Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

Erasca Securities Class Action

Erasca · ERAS-0015 cancer drug candidate and Erasca securities · Ongoing Litigation

About this case

A securities class action alleges that Erasca and two executives made false or misleading statements about the preclinical results and potential of the ERAS-0015 oncology drug candidate, while allegedly failing to disclose issues involving comparisons with a competing drug candidate and potential patent and trade secret disputes. The lawsuit has been filed, but no class has been certified; the matter is ongoing.

Case overview

Defendant company
Erasca
Product or service
ERAS-0015 cancer drug candidate and Erasca securities
Case name
Erasca, Inc. Securities Class Action
Court case number
3:26-cv-03481
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Erasca Lead Plaintiff Application
Lead Plaintiff Application

Participation information

Erasca Lead Plaintiff Application

Purchasers of Erasca common stock between January 14, 2025 and April 26, 2026, inclusive, may seek appointment as lead plaintiff.

A motion to serve as lead plaintiff was required by August 10, 2026. Investors may also remain absent class members and take no action at this stage.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Apply as lead plaintiff

Lead Plaintiff Application

Investors who purchased Erasca shares during the January 14, 2025 to April 26, 2026 class period and suffered losses were encouraged to contact the law firm regarding a possible lead-plaintiff appointment.

Contact Schall, Brown & Schwartz LLP regarding a possible lead-plaintiff appointment. Appointment as lead plaintiff is not required to participate in any recovery.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Apply as lead plaintiff

Faruqi & Faruqi investor inquiry

Investors who suffered losses in Erasca securities are encouraged to contact Faruqi & Faruqi regarding their options.

Contact James (Josh) Wilson at Faruqi & Faruqi to discuss potential options.

Type
Law Firm Signup
Reported proof requirement
Unclear

Erasca Investor Inquiry

The law firm invites Erasca investors to contact it regarding the securities class action, but specific eligibility criteria are not provided.

Contact Bronstein, Gewirtz & Grossman, LLC regarding representation in the Erasca securities class action.

Type
Law Firm Signup

Erasca Stockholder Case Inquiry

Purchasers of Erasca common stock between January 14, 2025, and April 26, 2026, inclusive.

Type
Law Firm Signup
Reported proof requirement
Unclear

Lead Plaintiff Application

Investors who suffered substantial losses in Erasca securities may provide information to seek appointment as lead plaintiff.

Submit information through the law firm’s case page.

Type
Lead Plaintiff
Apply as lead plaintiff

Bragar Eagel & Squire case inquiry

People who purchased or acquired Erasca common stock from January 14, 2025, through April 26, 2026, may contact Bragar Eagel & Squire regarding the action.

Contact Bragar Eagel & Squire attorneys at (212) 355-4648 to discuss potential legal rights.

Type
Law Firm Signup
Reported proof requirement
Unclear
Original announcement Original press release Original release Original press release Case announcement

Sources